Investigation of Metabolomics Differences Between Metabolic Syndrome and Healthy Individuals in Taiwan
NCT ID: NCT06363864
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1200 participants
OBSERVATIONAL
2024-04-14
2029-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Syndrome and Prediabetes
NCT07243821
The Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City
NCT00308672
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases
NCT07248371
Pancreatic Islet Function, Insulin Sensitivity, and Chronic Complications in Pre-Diabetes
NCT00172796
Population Research of Sublingual Microcirculation Data of Patients With Systemic Diseases
NCT02940275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy individuals
No interventions assigned to this group
Metabolic syndrome patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Having received oral antibiotics, immunosuppressants, and chemotherapy drugs in the past month
* Incapacity
* Limited disposing capacity
* Mental disorders or intellectual disabilities
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leeuwenhoek Laboratories Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LL-IRB-2401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.